|
1
|
Massimo R, Fassan M and Graham DY:
Epidemiology of gastric cancerGastric Cancer. Springer; Cham: pp.
23–34. 2015, PubMed/NCBI
|
|
2
|
Miyashiro I, Hiratsuka M, Sasako M, Sano
T, Mizusawa J, Nakamura K, Nashimoto A, Tsuburaya A and Fukushima
N: Gastric Cancer Surgical Study Group (GCSSG) in the Japan
Clinical Oncology Group (JCOG): High false-negative proportion of
intraoperative histological examination as a serious problem for
clinical application of sentinel node biopsy for early gastric
cancer: Final results of the Japan Clinical Oncology Group
multicenter trial JCOG0302. Gastric Cancer. 17:316–323. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nashimoto A, Akazawa K, Isobe Y, Miyashiro
I, Katai H, Kodera Y, Tsujitani S, Seto Y, Furukawa H, Oda I, et
al: Gastric cancer treated in 2002 in Japan: 200 annual report of
the JGCA nationwide registry. Gastric Cancer. 16:1–27. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bai LY, Chiu CF, Yang HR and Yang TY: 2230
Palliative gastrectomy does not prolong survival of metastatic
gastric cancer patients with both high CEA and high CA19-9 values
at diagnosis. Eur J Cancer. 51:S4102015. View Article : Google Scholar
|
|
5
|
Sun Z and Zhang N: Clinical evaluation of
CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with
neoadjuvant chemotherapy. World J Surg Oncol. 12:3972014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
He CZ, Zhang KH, Li Q, Liu XH, Hong Y and
Lv NH: Combined use of AFP, CEA, CA125 and CAl9-9 improves the
sensitivity for the diagnosis of gastric cancer. BMC gastroenterol.
13:872013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liang Y, Wang W, Fang C, Raj SS, Hu WM, Li
QW and Zhou ZW: Clinical significance and diagnostic value of serum
CEA, CA19-9 and CA72-4 in patients with gastric cancer. Oncotarget.
7:49565–49573. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang AP, Liu J, Lei HY, Zhang QW, Zhao L
and Yang GH: CA72-4 combined with CEA, CA125 and CAl9-9 improves
the sensitivity for the early diagnosis of gastric cancer. Clin
Chim Acta. 437:183–186. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shimada H, Noie T, Ohashi M, Oba K and
Takahashi Y: Clinical significance of serum tumor markers for
gastric cancer: A systematic review of literature by the Task Force
of the Japanese Gastric Cancer Association. Gastric Cancer.
17:26–33. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim JH, Jun KH, Jung H, Park IS and Chin
HM: Prognostic value of preoperative serum levels of five tumor
markers (Carcinoembryonic Antigen, CA19-9, Alpha-fetoprotein,
CA72-4, and CA125) in gastric cancer. Hepatogastroenterology.
61:863–869. 2014.PubMed/NCBI
|
|
11
|
Yu J, Zhang S and Zhao B: Differences and
correlation of serum CEA, CA19-9 and CA72-4 in gastric cancer. Mol
Clin Oncol. 4:441–449. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Docea AO, Mitruţ P, Cernea D, Georgescu
CC, Olimid D, Mărgăritescu C and Dumitrescu D: Immunohistochemical
expression of EGF, c-erbB-2 and EGFR in intestinal variant of
gastric adenocarcinomas. Rom J Morphol Embryol. 54:545–554.
2013.PubMed/NCBI
|
|
13
|
Docea AO, Mitruţ P, Grigore D, Pirici D,
Călina DC and Gofiţă E: Immunohistochemical expression of TGF beta
(TGF-β), TGF beta receptor 1 (TGFBR1), and Ki67 in intestinal
variant of gastric adenocarcinomas. Rom J Morphol Embryol. 53 3
Suppl:S683–S692. 2012.
|
|
14
|
Liu XH, Sun M, Nie FQ, Ge YB, Zhang EB,
Yin DD, Kong R, Xia R, Lu KH, Li JH, et al: Lnc RNA HOTAIR
functions as a competing endogenous RNA to regulate HER2 expression
by sponging miR-331-3p in gastric cancer. Mol Cancer. 13:922014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hofmann M, Stoss O, Shi D, Büttner R, van
de Vijver M, Kim W, Ochiai A, Rüschoff J and Henkel T: Assessment
of a HER2 scoring system for gastric cancer: Results from a
validation study. Histopathology. 52:797–805. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chiu CF, Yang HR, Yang MD, Jeng LB, Yang
TY, Sargeant AM and Bai LY: Palliative Gastrectomy Prolongs
Survival of Metastatic Gastric Cancer Patients with Normal
Preoperative CEA or CA19-9 Values: A Retrospective Cohort Study.
Gastroenterol Res Pract. 2016:68460272016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sougioultzis S, Syrios J, Xynos ID,
Bovaretos N, Kosmas C, Sarantonis J, Dokou A, Tzivras D, Zografos
G, Felekouras E, et al: Palliative gastrectomy and other factors
affecting overall survival in stage IV gastric adenocarcinoma
patients receiving chemotherapy: A retrospective analysis. Eur J
Surg Oncol. 37:312–318. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Marrelli D, De Stefano A, de Manzoni G,
Morgagni P, Di Leo A and Roviello F: Prediction of recurrence after
radical surgery for gastric cancer: A scoring system obtained from
a prospective multicenter study. Ann Surg. 241:247–255. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mihmanli M, Dilege E, Demir U, Coskun H,
Eroglu T and Uysalol MD: The use of tumor markers as predictors of
prognosis in gastric cancer. Hepatogastroenterology. 51:1544–1547.
2004.PubMed/NCBI
|
|
21
|
Lordick F and Janjigian YY: Clinical
impact of tumour biology in the management of gastroesophageal
cancer. Nat Rev Clin Oncol. 13:348–360. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Verlato G, Roviello F, Marchet A,
Giacopuzzi S, Marrelli D, Nitti D and de Manzoni G: Indexes of
surgical quality in gastric cancer surgery: Experience of an
Italian network. Ann Surg Oncol. 16:594–602. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim KM, Bilous M, Chu KM, Kim BS, Kim WH,
Park YS, Ryu MH, Sheng W, Wang J, Chao Y, et al: Human epidermal
growth factor receptor 2 testing in gastric cancer: Recommendations
of an Asia-Pacific task force. Asia Pac J Clin Oncol. 10:297–307.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ieni A, Barresi V, Rigoli L, Caruso RA and
Tuccari G: HER2 status in premalignant, early, and advanced
neoplastic lesions of the stomach. Dis Markers. 2015:2348512015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Luis M, Tavares A, Carvalho LS,
Lara-santos L, Araújo A and De mello RA: Personalizing therapies
for gastric cancer: Molecular mechanisms and novel targeted
therapies. World J Gastroenterol. 19:6383–6397. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Byström P, Berglund A, Nygren P, Wernroth
L, Johansson B, Larsson A, Einarsson R and Glimelius B: An
explorative study on the clinical utility of baseline and serial
serum tumour marker measurements in advanced upper gastrointestinal
cancer. Oncol Rep. 24:1645–1652. 2010.PubMed/NCBI
|
|
27
|
Moore RG, McMeekin DS, Brown AK,
DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC
Jr and Skates SJ: A novel multiple marker bioassay utilizing HE4
and CA125 for the prediction of ovarian cancer in patients with a
pelvic mass. Gynecol Oncol. 112:40–46. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ishida M, Kagawa S, Shimoyama K, Takehara
K, Noma K, Tanabe S, Shirakawa Y, Tazawa H, Kobayashi H and
Fujiwara T: Trastuzumab-based photoimmunotherapy integrated with
viral HER2 transduction inhibits peritoneally disseminated
HER2-negative cancer. Mol Cancer Ther. 15:402–411. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Emoto S, Ishigami H, Yamashita H,
Yamaguchi H, Kaisaki S and Kitayama J: Clinical significance of
CA125 and CA72-4 in gastric cancer with peritoneal dissemination.
Gastric Cancer. 15:154–161. 2012. View Article : Google Scholar : PubMed/NCBI
|
